RxDoctor Payments DataLook up a doctor →

John Kaczmar, MD

Medical Oncology · Charleston, SCNPI 1134448079

Payments from drug & device makers

$7,747,285in general payments, 2019–2025

Across 269 payments — averaging $28,800 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$6.8M
  • Regeneron$332K
  • Ascendis Pharma Endocrinology Inc$145K
  • GSK$142K
  • AVEO Pharmaceuticals, Inc.$131K
  • Merck Healthcare Kgaa$76K
  • plus $91K from 13 others
$10,864in research payments, 2019–2025

Across 60 payments — averaging $181.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$11K

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,747,285 in reported general payments places this provider in the 95th percentile of 29 medical oncology providers in South Carolina.

See all medical oncology providers in South Carolina

Medicare billing

Part B allowed, 2024
$69,876
Medicare patients
238
Services billed
952

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →